Quantcast

Latest Kathy Giusti Stories

2011-09-20 22:26:59

The John Theurer Cancer Center at Hackensack University Medical Center, a top 50 U.S. News best hospital for cancer, is one of the first four clinical sites enrolling patients in a landmark study designed to uncover the molecular segments and variations of multiple myeloma.

2011-08-03 15:00:00

SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 3, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) and the Multiple Myeloma Research Foundation (MMRF) today announced the initiation of an expanded access program for carfilzomib, a selective, next-generation proteasome inhibitor.

2008-10-14 09:00:44

The Multiple Myeloma Research Consortium has initiated a three-drug combination study of elotuzumab, a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with Revlimid, and dexamethasone for the treatment of multiple myeloma in patients who are experiencing a relapse.

2008-08-22 18:00:43

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a clinical trial with the oral immunomodulatory agent pomalidomide (CC-4047) in patients who have received at least two prior therapies including treatments with REVLIMID(R) (lenalidomide) and VELCADE(R) (bortezomib) for Injection.

2008-08-13 09:01:15

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a four-drug combination study with REVLIMID(R) (lenalidomide), VELCADE(R) (bortezomib) for Injection, DOXIL(R) (doxorubicin HCl liposome injection) and dexamethasone for the treatment of multiple myeloma in patients who are previously untreated.

2008-07-18 15:00:57

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase I/II study of elotuzumab (also known as Huluc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with VELCADE(R) (bortezomib) for Injection for the treatment of relapsed multiple myeloma.

2008-06-27 15:03:00

The Multiple Myeloma Research Consortium (MMRC) today announced the addition of two Member Institutions.


Word of the Day
postliminy
  • In Roman antiquity, the return of a person who had been banished, or taken prisoner by an enemy, to his old condition and former privileges.
  • In international law, that right by virtue of which persons and things taken by an enemy in war are restored to their former status when coming again under the power of the nation to which they belonged.
The word 'postliminy' comes from a Latin word meaning 'threshold'.